BiotechTube
Home/Orion Corporation/Mikael Hjort
MH

Mikael Hjort

Senior Vice President, Fermion

Orion Corporation

Therapeutic Areas

OncologyCentral Nervous System (CNS) disordersRespiratory diseasesPainWomen's Health

Orion Corporation Pipeline

DrugIndicationPhase
ODM-208Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2
ODM-209Undisclosed OncologyPhase 1
ODM-212Malignant Pleural Mesothelioma (MPM) & Epithelioid Hemangioendothelioma (EHE)Phase 2
Darolutamide (Nubeqa®)Prostate Cancer (Various stages)Marketed / Phase 3
LevomedetomidinePost-operative Sedation / AgitationPhase 3

Leadership Team at Orion Corporation

OV
Outi Vaarala
Senior Vice President, Research and Development
View full Orion Corporation profile